Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$4.65 -4.6%	$4.01	$1.58 ▼ $7.27	$413.80M	-0.6	1.24 million shs	2.09 million shs
GERN Geron	$1.27 -3.4%	$1.50	$1.17 ▼ $5.34	$805.70M	0.76	11.45 million shs	9.64 million shs
RCKT Rocket Pharmaceuticals	$7.04 +5.1%	$7.18	$4.55 ▼ $26.98	$751.77M	1.02	1.40 million shs	2.67 million shs
RYTM Rhythm Pharmaceuticals	$60.72 -6.0%	$56.70	$35.17 ▼ $68.58	$3.86B	2.36	543,549 shs	1.08 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-4.33%	-9.63%	+40.33%	+22.24%	+140.67%
GERN Geron	-3.44%	-11.54%	-1.17%	-56.83%	-66.80%
RCKT Rocket Pharmaceuticals	+5.47%	-10.43%	+46.97%	-31.91%	-69.36%
RYTM Rhythm Pharmaceuticals	-5.78%	-4.83%	+5.18%	+2.60%	+56.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.2499 of 5 stars	3.6	1.0	0.0	3.3	4.2	1.3
GERN Geron	3.9389 of 5 stars	4.4	1.0	1.3	2.4	3.3	0.6
RCKT Rocket Pharmaceuticals	4.7759 of 5 stars	4.5	1.0	4.7	3.5	5.0	0.6
RYTM Rhythm Pharmaceuticals	3.6176 of 5 stars	3.5	1.0	4.3	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.13	Buy	$9.00	93.76% Upside
GERN Geron	2.78	Moderate Buy	$5.06	300.20% Upside
RCKT Rocket Pharmaceuticals	2.92	Moderate Buy	$43.00	510.80% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$75.38	24.15% Upside

Current Analyst Ratings Breakdown

Latest AMLX, RCKT, RYTM, and GERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	GERN Geron	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$4.00 ➝ $1.50
5/7/2025	AMLX Amylyx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $10.00
5/7/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$66.00 ➝ $72.00
5/6/2025	AMLX Amylyx Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/9/2025	RCKT Rocket Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/8/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
4/8/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$81.00 ➝ $92.00
4/8/2025	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $80.00
4/7/2025	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$3.00 ➝ $7.00
4/7/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$80.00 ➝ $91.00
4/7/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$63.00 ➝ $63.00

(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	4.74	$0.84 per share	5.51	$6.42 per share	0.72
GERN Geron	$76.99M	10.46	N/A	N/A	$0.46 per share	2.75
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A
RYTM Rhythm Pharmaceuticals	$130.13M	29.68	N/A	N/A	$2.87 per share	21.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	$49.27M	-$4.44	N/A	N/A	N/A	N/A	-36.97%	-29.61%	N/A
GERN Geron	-$184.13M	-$0.27	N/A	N/A	N/A	-682.48%	-67.53%	-45.46%	N/A
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.73	N/A	N/A	N/A	N/A	-62.62%	-54.17%	N/A
RYTM Rhythm Pharmaceuticals	-$184.68M	-$2.81	N/A	N/A	N/A	-230.07%	-367.36%	-77.47%	N/A

Latest AMLX, RCKT, RYTM, and GERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.43	-$0.42	+$0.01	-$0.42	N/A	N/A
5/7/2025	Q1 2025	GERN Geron	-$0.04	-$0.03	+$0.01	-$0.03	$49.88 million	$39.60 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/4/2025	Q4 2024	AMLX Amylyx Pharmaceuticals	-$0.49	-$0.55	-$0.06	-$0.55	N/A	($0.67) million
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A
2/26/2025	Q4 2024	GERN Geron	-$0.04	-$0.04	N/A	-$0.04	$45.29 million	$47.54 million
2/26/2025	Q4 2024	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.72	-$0.03	-$0.72	$38.48 million	$41.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	$1.02	21.87%	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	4.55	4.55
GERN Geron	0.04	2.89	2.74
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05
RYTM Rhythm Pharmaceuticals	N/A	3.49	3.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
GERN Geron	73.71%
RCKT Rocket Pharmaceuticals	98.39%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
GERN Geron	7.42%
RCKT Rocket Pharmaceuticals	28.50%
RYTM Rhythm Pharmaceuticals	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.08 million	60.53 million	Optionable
GERN Geron	70	636.91 million	585.76 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.60 million	58.02 million	Optionable

AMLX, RCKT, RYTM, and GERN Headlines

Recent News About These Companies

Tudor Investment Corp ET AL Invests $853,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 9 at 4:23 AM | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 6.6% on Disappointing Earnings

May 9 at 3:41 AM | americanbankingnews.com

Needham & Company LLC Boosts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $72.00

May 9 at 2:47 AM | americanbankingnews.com

Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ...

May 8 at 8:10 AM | finance.yahoo.com

Mariner LLC Invests $254,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 8 at 3:28 AM | marketbeat.com

Rhythm Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation

May 7 at 3:20 PM | seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates

May 7 at 9:10 AM | zacks.com

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

May 7 at 7:00 AM | globenewswire.com

Hsbc Holdings PLC Invests $921,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 7 at 4:00 AM | marketbeat.com

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

May 6 at 8:00 AM | globenewswire.com

Baker BROS. Advisors LP Sells 314,117 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 6 at 7:39 AM | marketbeat.com

Bellevue Group AG Purchases 7,896 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 6 at 6:33 AM | marketbeat.com

Schonfeld Strategic Advisors LLC Acquires 29,165 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 6 at 4:48 AM | marketbeat.com

Tower Research Capital LLC TRC Acquires 4,161 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 6 at 3:51 AM | marketbeat.com

Aquatic Capital Management LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 4, 2025 | marketbeat.com

Voya Investment Management LLC Sells 5,663 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 3, 2025 | marketbeat.com

PDT Partners LLC Acquires 32,083 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 2, 2025 | marketbeat.com

Rhythm Pharmaceuticals (RYTM) Projected to Post Earnings on Wednesday

May 2, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells $438,964.60 in Stock

May 2, 2025 | insidertrades.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Bought by Price T Rowe Associates Inc. MD

May 2, 2025 | marketbeat.com

First Trust Advisors LP Has $6.63 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

May 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX, RCKT, RYTM, and GERN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$4.64 -0.23 (-4.62%)

Closing price 05/8/2025 03:59 PM Eastern

Extended Trading

$4.58 -0.06 (-1.40%)

As of 05/8/2025 07:24 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Geron NASDAQ:GERN

$1.26 -0.05 (-3.44%)

Closing price 05/8/2025 03:59 PM Eastern

Extended Trading

$1.28 +0.02 (+1.19%)

As of 04:28 AM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Rocket Pharmaceuticals NASDAQ:RCKT

$7.04 +0.34 (+5.07%)

Closing price 05/8/2025 04:00 PM Eastern

Extended Trading

$7.13 +0.09 (+1.29%)

As of 06:33 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Rhythm Pharmaceuticals NASDAQ:RYTM

$60.72 -3.91 (-6.05%)

Closing price 05/8/2025 04:00 PM Eastern

Extended Trading

$60.72 0.00 (0.00%)

As of 05:59 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time